Novo Nordisk’s Wegovy and copyright, each powered by semaglutide, have revolutionized obesity treatment by unparalleled weight loss success.In Oct 2024, Novo Nordisk posted a review on scientific journal Mother nature a few novel glucose-sensitive insulin NNC2215 which will minimize the potential risk of hypoglycemia in animal models.[sixty seven